Starling Oncology (STLNW) Free Cash Flow (2020 - 2026)

Starling Oncology (STLNW) has reported Free Cash Flow for 7 consecutive years, with $11.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Free Cash Flow rose 196.69% year-over-year to $11.0 million; the trailing twelve-month figure through Jun 2026 stood at -$3.3 million (up 75.22% YoY), and the FY2025 full-year result was -$27.8 million, up 8.38% from the prior year.
• Free Cash Flow grew to $11.0 million in Q2 2026 per STLNW's latest filing, from -$3.3 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $11.0 million in Q2 2026 and bottomed at -$21.6 million in Q3 2022.
• Historically, Free Cash Flow has averaged -$8.8 million across 5 years, with a median of -$10.5 million in 2023.
• The sharpest annual moves came in 2022 and 2026: Free Cash Flow slumped 11501.94% in 2022, then jumped 196.69% in 2026.
• Over 5 years, Free Cash Flow stood at -$16.0 million in 2022, then jumped by 70.27% to -$4.8 million in 2023, then surged by 147.22% to $2.2 million in 2024, then fell by 3.21% to $2.2 million in 2025, then jumped by 407.69% to $11.0 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered $11.0 million, -$3.3 million, and $2.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.